Literature DB >> 2492083

Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.

G C White1, C W McMillan, H S Kingdon, C B Shoemaker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2492083     DOI： 10.1056/NEJM198901193200307

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

Review 1.  Cardiovascular drugs.

Authors:  P Vermeij
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 2.  Plasma-derived medicines: access and usage issues.

Authors:  Albert Farrugia; Josephine Cassar
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

Review 3.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

4.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 5.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

6.  Current status of a recombinant antihemophilic factor VIII clinical trial organized by Baxter.

Authors:  I Scharrer
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

Review 7.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

Review 8.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 9.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 10.  Factor VIII safety: plasma-derived versus recombinant products.

Authors:  Alessandro Gringeri
Journal:  Blood Transfus       Date:  2011-04-12       Impact factor: 3.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.